spike protein of SARS-Co V-2
GPTKB entity
Statements (68)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:protein
|
gptkbp:bfsLayer |
6
|
gptkbp:bfsParent |
gptkb:tixagevimab
|
gptkbp:code |
SARS-Co V-2 genome
|
gptkbp:combatants |
AC E2 receptor
|
gptkbp:composed_of |
amino acids
|
gptkbp:financial_performance |
glycosylation
|
gptkbp:function |
facilitates entry into host cells
|
gptkbp:has_variants |
gptkb:Delta_variant
Omicron variant |
https://www.w3.org/2000/01/rdf-schema#label |
spike protein of SARS-Co V-2
|
gptkbp:is_aimed_at |
preventive measures
therapeutic interventions vaccines monoclonal antibodies therapeutics neutralizing antibodies vaccine candidates broadly neutralizing antibodies |
gptkbp:is_analyzed_in |
structural stability
structural biology studies mutation effects antigenic properties |
gptkbp:is_associated_with |
immune evasion
|
gptkbp:is_characterized_by |
S1 and S2 subunits
glycoprotein structure receptor binding domain |
gptkbp:is_critical_for |
viral infectivity
|
gptkbp:is_involved_in |
antigen presentation
pathogen recognition viral replication host immune response cellular signaling viral pathogenesis viral assembly pathogen-host dynamics antibody binding cell membrane fusion cellular entry pathways host cell interaction viral entry mechanism viral fusion |
gptkbp:is_linked_to |
vaccine efficacy
viral load transmission dynamics vaccine breakthrough infections COVID-19 severity |
gptkbp:is_part_of |
viral envelope
viral structure viral glycoproteins viral life cycle |
gptkbp:is_represented_in |
gptkb:healthcare_organization
infected cells vaccine-induced immunity |
gptkbp:is_studied_in |
COVID-19 research
clinical trials vaccine development therapeutic antibodies vaccine safety immune response modulation antiviral strategies vaccine formulation vaccine design vaccine response assessment |
gptkbp:is_used_in |
diagnostic assays
|
gptkbp:part_of |
gptkb:SARS-Co_V-2
|
gptkbp:recognizes |
serological tests
|
gptkbp:trigger_type |
immune response
|